atai Beckley (formed from atai Life Sciences' combination with Beckley Psytech) develops psychedelic-based therapeutics for treatment-resistant depression and mental health conditions.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Louis Bacon / Moore | 56 | New buy | 952,380 | $3,371,425 | 0.1% |
| Ruane Cunniff / Sequoia Fund | 76 | New buy | 42,112 | $149,076 | 0.0% |
| Ancora | 42 | New buy | 1,147 | $4,060 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-20.